Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent sarcoma.
Recurrent Adult Soft Tissue Sarcoma
DEVICE: Cryosurgery|BIOLOGICAL: NK immunotherapy
Relief degree, It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）, 3 months
Progress free survival（PFS）, 1 year|Overall survival（OS）, 3 years
By enrolling patients with recurrent sarcoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and natural killer (NK) cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).